Publikationen
2011
Engler B, Koehler C, Hoffmann C, Landgraf W, Bilz S, Schoner C, Bornstein SR, Hanefeld M
Relationship between HbA1c on target, risk of silent hypoglycemia and glycemic variability in patients with Type 2 diabetes mellitus
Exp Clin Endocrinol. Diabetes 2011; 119:59-61
Pistrosch, F. Natali A, Hanefeld M.
Is Hyperglycemia a cardiovascular risk factor?
Diabetes care, vol. 34, Suppl. 2, May 2011
Thomas A, Schnell O, Hanefeld M, Mastrototaro J, Heinemann L.
O “Pentágono da Glicose”: um modelo integrative de diferentes parametros de perfis de glucose para a avaliacao do controle da diabetes
Diabetes Clinica No 01/2011: 72-80
2010
Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis
PS, Jones NP, Home PD.:
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial.
Eur Heart J. 2010 Apr;31(7):824-31. Epub 2010 Jan 29.
Krone W, Hanefeld M, Meyer HF, Jung T, Bartlett M, Yeh CM, Rajman I, Prescott
MF, Dole WP.:
Comparative efficacy and safety of aliskiren and irbesartan in patients with
hypertension and metabolic syndrome.
J Hum Hypertens. 2010 Apr 8: 1-10
Hanefeld M, Koehler C, Hoffmann C, Wilhelm K, Kamke W, Gerstein H.:
Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes.
Diabet Med. 2010 Feb;27(2):175-80.
Hanefeld M, Schönauer M, Forst T.:
Glycemic control and cardiovascular benefit: What do we know today?
Dtsch Med Wochenschr. 2010 Feb;135(7):301-7. Epub 2010 Feb 9. Review.
German.
Hanefeld M,Schönauer M., Forst T.
Blutzucker-Senkung und kardiovaskulärer Vortei: Was wissen wir heute? DMW 2010; 135: 301-307
Hanefeld M., Forst Th.
Comment: Dapagliflozin, an SGLT2 inhibitor, for diabetes
Lancet, Vol 375, June 26, 2010:2196-2198
NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA,
Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR,
Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D,
Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H,
Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F,
Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten
GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S,
Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM.:
Effect of valsartan on the incidence of diabetes and cardiovascular events.
Engl J Med. 2010 Apr 22;362(16):1477-90. Epub 2010 Mar 14. Erratum in: N Engl
J Med. 2010 May 6;362(18):1748.
Pfützner A, Schöndorf T, Hanefeld M, Forst T.:
High-Sensitivity C-Reactive Protein Predicts Cardiovascular Risk in Diabetic and Nondiabetic Patients: Effects of Insulin-Sensitizing Treatment with Pioglitazone.
J Diabetes Sci Technol. 2010 May 1;4(3):706-716.
Schernthaner G, Barnett AH, Betteridge DJ, Carmena R, Ceriello A, Charbonnel B,
Hanefeld M, Lehmann R, Malecki MT, Nesto R, Pirags V, Scheen A, Seufert J,
Sjohölm A, Tsatsoulis A, DeFronzo R.:
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis.
Diabetologia. 2010 Jul;53(7):1258-69. Epub 2010 Mar 31.
2009
Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A; Study Investigators:
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.
Am J Cardiovasc Drugs. 2009;9(2):91-101
Büssemaker E, Herbrig K, Pistrosch F, Palm C, Passauer J:
Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients.
Atherosclerosis. 2009 Dec;207(2):567-72
Hanefeld M:
Normale Blutzuckerkontrolle oder HbA1c<7% bei Typ-2-Diabetes – hat 2008 die diabetologische Welt erschüttert oder dringt Sonne durch den Nebel?
Diabetologie 2009;4:29-31
Hanefeld M, Bornstein SR, Pistrosch F:
Shifting the disease management paradigm from glucose: what are the cons?
Diabetes Care. 2009 Nov;32 Suppl 2:S353-6
Hanefeld M, Forst T, Pfützner A:
Datenlage zum kardiovaskulären Nutzen-Risiko-Profil von Pioglitazon.
Diabetes, Stoffwechsel und Herz, Bd 18, 1/2009: 37-42
Hanefeld M, Karasik A, Koehler C, Westermeier T, Chiasson JL:
Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial.
Diab Vasc Dis Res. 2009 Jan;6(1):32-7
Hanefeld M, Schaper F, Koehler C, Bergmann S, Ugocsai P, Stelzer J, Schmitz G:
Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study.
Horm Metab Res. 2009 Feb;41(2):132-6
Hanefeld M:
The role of pioglitazone in modifying the atherogenic lipoprotein profile.
Diabetes Obes Metab. 2009 Aug;11(8):742-56
Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team:
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Lancet, 2009 Jun 20;373(9681):2125-35
Koutnikova H, Laakso M, Lu L, Combe R, Paananen J, Kuulasmaa T, Kuusisto J, Häring HU, Hansen T, Pedersen O, Smith U, Hanefeld M, Williams RW, Auwerx J:
Identification of the UBP1 locus as a critical blood pressure determinant using a combination of mouse and human genetics.
PLoS Genet. 2009 Aug;5(8):e1000591
Ott P, Benke I, Stelzer J, Köhler C, Hanefeld M:
"Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice.
Dtsch Med Wochenschr. 2009 Feb;134(7):291-7
Hanefeld M., Karasik A, Koehler C, Westermeier T, Saunders G, Chiasson JL
Metabolic syndrome and ist single traits as risk factors of diabetes in people with impaired glucose tolerance: The STOP-NIDDM trial.
Diabetes Care 2009 Jan;6(1):32-7
Pfützner A, Hanefeld M, Forst T:
Insulin glargin und Krebs: Wissenschaftlich begründete Warnung oder Panikmache?
Diabetes, Stoffwechsel und Herz, Band 18, 5/2009,S. 423-426
Reimann M, Bonifacio E, Solimena M, Schwarz PE, Ludwig B, Hanefeld M, Bornstein SR:
An update on preventive and regenerative therapies in diabetes mellitus.
Pharmacol Ther. 2009 Mar;121(3):317-31
Schwarz PE, Li J, Reimann M, Schutte AE, Bergmann A, Hanefeld M, Bornstein SR, Schulze J, Tuomilehto J, Lindström J:
The Finnish Diabetes Risk Score is associated with insulin resistance and progression towards type 2 diabetes.
J Clin Endocrinol Metab. 2009 Mar;94(3): 920-6
Temelkova-Kurktschiev TS, Kurktschiev DP, Vladimirova-Kitova LG, Koehler C, Henkel E, Todorova BR, Schaper F, Fuecker K, Hanefeld M:
Pulse pressure is a strong predictor of cardiovascular risk: Data of the risk factors in impaired glucose tolerance for atherosclerosis and diabetes and the Sofia Metabolic Syndrome studies.
Folia Med (Plovdiv). 2009 Jan-Mar;51(1):34-41
Thomas A, Schönauer M, Achermann F, Schnell O, Hanefeld M, Ziegelasch HJ, Mastrototaro J, Heinemann L:
The "glucose pentagon": assessing glycemic control of patients with diabetes mellitus by a model integrating different parameters from glucose profiles.
Diabetes Technol Ther. 2009 Jun;11(6):399-409
Hanefeld M, Bornstein SR, Pistrosch F: Shifting the disease management paradigm from glucose: what are the cons?
Diabetes Care 32 Suppl 2:S353-S356, 2009
Bussemaker E, Herbrig K, Pistrosch F, Palm C, Passauer J:
Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients.
Atherosclerosis 207:567-572, 2009
Pistrosch F, Schaper F, Passauer J, Koehler C, Bornstein SR, Hanefeld M:
Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Horm.Metab Res. 41:104-108, 2009
2008
Hanefeld M, Schaper F.
Acarbose: oral antidiabetes drug with additional cardiovascular benefits
Future Drugs, Expert Review of Cardiovascular Therapy
Febr. 2008, Vol. 6, No 2: 153-163
Rothe U, Mueller G, Schwarz P, Seifert M, Kunath H, Koch R. Bergmann S, Julius U, Bronstein S, Hanefeld M, Schulze J
Evaluation of a Diabetes Management System based on Practice Guidelines, Integrated Care and Continuous Quality Management in a Federal State of Germany: a Population-based Approach to Health Care Research
Diabetes Care, published online March 10, 2008
Milicevic Z, Raz I, Beattie S, Campaigne B, Sarwat S, Gromniak E, Kowalska I, Galic E, Tan M, Hanefeld M.
Natural History of Cardiovascular Disease in Patients with Diabetes
Diabetes Care 31: S155-S160, 2008
Mohler ER, Ballantyne CM. Davidson MH, Hanefeld M, Ruilope LM. Johnson JL Zalewski A
The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2, Activity and Cardiovascular Biomarkers in Patients with stable coronary heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
J.Am.Coll.Cardiol. 2008; 51; 1632-1641
Ludvik B, Hanefeld M, Pacini G
Improved metabolic control by Ipomoea batatas (CAIapo) is associated with increased adiponectin and decreased fibrtinogen levels in type 2 diabetic subjects
Diabetes, Obesity and Metabolism 10, 2008, 856-592
Leohnardt W, Pfützner A, Müller J, Pietzsch J, Forst Th, Karagiannis E, Lübben G, Hanefeld M
Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: A sub-analysis from the PIOSTAT study
Atherosclerosis 201 (2008): 155-162
Pistrosch F:
Ambulatory blood pressure vs. office blood pressure in type 2 diabetes.
Am.J.Hypertens. 21:372, 2008
Randriamboavonjy V, Pistrosch F, Bolck B, Schwinger RH, Dixit M, Badenhoop K, Cohen RA, Busse R, Fleming I:
Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone.
Circulation 117:52-60, 2008
2007
Hanefeld, M., Marx N, Pfützner A, Baurech W, Lübben G, Karagiannis E, Stier U, Forst Th.
Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Risk Patients with elevated high sensitivity C-reaktive protein
J Am Coll Cardiol 2007; Vol 49, No 3:290-7
Hanefeld M, Patwardhan R, Jones PJ for the Rosiglitazone Clinical Trials study Group
A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes
Nutrition, Metabolism & Cardiovascular Diseases (2007) 17, 13-23
Hanefeld M, Schaper F. Ceriello A,
Geschichte und Definitionen des metabolischen Syndroms
Der Internist Bnd. 48, Heft 2, Febr. 2007, 117-125
Hanefeld M, Koehler C, Gallo S, Benke I, Ott P
Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study
Cardiovascular Diabetology 2007, 6: 13
Hanefeld M.
Normnahe postprandiale Hyperglykämie – eine essenzielle Komponente gutter Diabeteskontrolle und Prävention kardiovaskulärer Erkrankungen- Paul Langerhans-Vorlesung 2007 –
Diabetologie und Stoffwechsel 2007; 2: 362-369
Forst Th, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Koehler C, Baurecht W, Hohberg C. Hanefeld M
Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk- the PIOSTAT Study
Metabolism Clinical and Experimental 56 (2007): 491-496
Pistrosch F, Reissmann, E, Wildbrett J, Koehler C, Hanefeld M
Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patients
American Journal of Hypertension, 2007, 20: 541-545
Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock S, Zambanini A, Jones N, Gomis R, Home Ph for the Record Study Group
Rosiglitazone lowers ambulatory blood pressure compared with metformin and sulfonylureas in people with type 2 diabetes. The RECORD study
Diabetic Medicine, 2007, 24: 626-634
Home PD, Jones NP, Pacock SJ, Beck Nielsen H, Gomis R, Hanefeld M, Komajda M, Curtis P. for the Record Study Group
Rosiglitazone RECORD study: glucose control outcomes at 18 month
Diabetic Medicine, 2007, 24
Raz I, Hanefeld M, Xu L. Caria C. Williams-Herman D, Khatamie H, Sitagliptin Study 023 Group
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as nonotherapy in patients with type 2 diabetes mellitus
Diabetologia, 2006
Pfützner A, Hanefeld M, Lübben G, Weber MM, Karagiannis E, Köhler C, Hohberg C, Forst T.
Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk - results from the PIOSTAT study.
Horm Metab Res. 2007 39(10):764-8
Koehler C, Ott P, Benke I, Hanefeld M; DIG Study Group
Comparison of the prevalence of the metabolic syndrome by WHO, AHA/NHLBI, and IDF definitions in a German population with type 2 diabetes: the Diabetes in Germany (DIG) Study.
Horm Metab Res. 2007 39(9):632-5
Ludvik B, Hanefeld M, Pacini G
Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects.
Diabetes Obes Metab. 2007 21
Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group
Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis.
N Engl J Med. 2007 5;357(1):28-38
Henkel E, Gallo S, Siegert G, Koehler C, Hanefeld M
Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis.
Blood Coagul Fibrinolysis. 2007 18(4):327-34
Monnier L, Colette C, Leiter L, Ceriello A, Hanefeld M, Owens D, Tajima N, Tuomiletho J, Davidson J; PGR Group
The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.
Diabetes Care. 2007 30(1):185-6; author reply 187-8
Schwarz PE, Bornstein SR, Hanefeld M
Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjects.
Diabetes Res Clin Pract. 2007 77(1):148-50
Pistrosch F, Reissmann E, Wildbrett J, Koehler C, Hanefeld M:
Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patients.
Am.J.Hypertens. 20:541-545, 2007
Bussemaker E, Pistrosch F, Forster S, Herbrig K, Gross P, Passauer J, Brandes RP: Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide.
Am.J.Physiol Heart Circ.Physiol 293:H541-H547, 2007
Gross P, Pistrosch F:
PPAR agonists in diabetic nephropathy.
Nephrol.Dial.Transplant. 22:2095-2096, 2007
2006
Kazda C, Hülstrunk H, Helsber K, Langer F, Forst Th, Hanefeld M
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: A randomised controlled trial in patients with type 2 diabetes beginning insulin therapy
Journal of Diabetes and its Complications 20 (2006): 145-152
Tschuchia T et al.
Association of the calpain-10 gene with type 2 diabetes in Europeans : Results of pooled and meta-analyses.
Mol. Genet Metab. 2006, Jul 10:
Hanefeld M, Metzler W. Köhler C, Schaper F
Therapie des metabolischen Syndroms
Herz 3/06, Urban &Vogel Verlag, : 246-54
Hanefeld M, Pfützner A, Forst T, Lübben G
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study
Current Medical Research and opinion, Vol. 22, No. 6, 2006, 1211-15
Hanefeld M.
Treatment of impaird glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial.
Endocr. Pract. 2006, Jan-Feb; 12 Suppl 1: 56-9
Hanefeld M.
Das Metabolische Syndrom – Konzept für eine ganzheitliche Diagnostik und Therapie eines Clusters von Stoffwechselkrankheiten
Diabetologie und Stoffwechsel, 2006; 1:303-304
Hanefeld M. Pfützner A, Forst T, Lübben G
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study
Curr Med Res Opin 2006; 22 (6) :1211-16
Herbrig K, Gebler K, Oelschlaegel U, Pistrosch F, Foerster S, Wagner A, Gross P, Passauer J:
Kidney transplantation substantially improves endothelial progenitor cell dysfunction in patients with end-stage renal disease.
Am.J.Transplant. 6:2922-2928, 2006
Pistrosch F, Koehler C, Wildbrett J, Hanefeld M:
Relationship between diurnal glucose levels and HbA1c in type 2 diabetes.
Horm.Metab Res. 38:455-459, 2006
Palm C, Pistrosch F, Herbrig K, Gross P:
Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Am.J.Med. 119:S87-S92, 2006
Herbrig K, Pistrosch F, Foerster S, Gross P:
Endothelial progenitor cells in chronic renal insufficiency.
Kidney Blood Press Res. 29:24-31, 2006
Herbrig K, Pistrosch F, Gross P, Palm C:
Resumption of peritoneal dialysis after transcutaneous treatment of a peritoneal leakage using fibrin glue.
Nephrol.Dial.Transplant. 21:2037-2038, 2006
Pistrosch F, Bussemaker E, Gross P:
An old patient with end stage renal disease and sudden onset of confusion and lethargy.
Nephrol.Dial.Transplant. 21:813-815, 2006
Herbrig K, Haensel S, Oelschlaegel U, Pistrosch F, Foerster S, Passauer J: Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells.
Ann.Rheum.Dis. 65:157-163, 2006
2005
M. Hanefeld
Current Medical Research and Opinion
Vo. 21, suppl. 1, 2005, S 41-48
Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M
Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
Metabolism. 2005, Sept; 54(9): 1168-73
Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, et al.
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol
Diabetologia (2005) 48: 1726-1735
Barter P, Hanefeld M
Dyslipidaemia and the metabolic syndrome: critical issues in improving CVC risk reduction
The British Journal of Diabetes & Vascular Disease, Vol. 5, Suppl. 1, July/Aug. 2005: S1
Schaper F, Ott P, Hanefeld M
Multimodales Management gegen das metabolische Syndrom
Klinikarzt 2005; 34(12)
Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes
Diabetologia, 2005
Ceriello A, Hanefeld M, Leiter L, Monnier L, Owens D, Tajima N, Tuomilehto J
The Postprandial State and Endothelial Dysfunction
2005 Jul;48(7):1423-4; author reply 1425-6. Epub 2005 Jun 10
Pistrosch F, Herbrig K, Oelschlaegel U, Richter S, Passauer J, Fischer S, Gross P: PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells.
Atherosclerosis 183:163-167, 2005
Passauer J, Pistrosch F, Lassig G, Herbrig K, Bussemaker E, Gross P, Fleming I: Nitric oxide- and EDHF-mediated arteriolar tone in uremia is unaffected by selective inhibition of vascular cytochrome P450 2C9.
Kidney Int. 67:1907-1912, 2005
Passauer J, Pistrosch F, Bussemaker E:
Nitric oxide in chronic renal failure.
Kidney Int. 67:1665-1667, 2005
Passauer J, Pistrosch F, Bussemaker E, Lassig G, Herbrig K, Gross P:
Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide.
J.Am.Soc.Nephrol. 16:959-965, 2005
2004
Erdmann, E., Hanefeld, M.
Glitazone – eine antidiabetische Substanzklasse aus kardiologischer Sicht
Deutsches Ärzteblatt, Jg. 101, Heft 44, Okt. 2004: 2954-2961
Temelkova-Kurktschiev, Th.; Hanefeld, M.
The Lipid Triad in Type 2 Diabetes – Prevalence and Relevance of Hypertriglyceridaemia/ Low High-Density Lipoprotein Syndrome in Type 2 Diabetes
Exp. Clin Endocrinol Diabetes, 112, 2004: 75-79
Hanefeld, M. Cagatay, M. Petrowitsch T. Neuser D. Petzinna D. Rupp M.
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
European Heart Journal, 25, 2004:10-16
Fischer S, Julius U. Hanefeld M. Fücker K, Gräßler J, Towers W, Schwanebeck U, Schulze J, Schwarz P
Das Vorkommen von Genotyp 1.1 im SNP-44 des CAPN 10-Gens ist im Stadium des Typ 2 Diabetes mit erhöhten Insulin- und C-Peptid-Werten assoziiert
Diabetes und Stoffwechsel 13, 2004: 3-9
Ott, P., Hanefeld, M.
“Dresdner Trunk” – proteinsubstituiertes modifiziertes Fasten
Ernährung & Medizin, 19, 2004: 27-30
Hanefeld M., Chiasson J.-L., Koehler C., Henkel E., Schaper F., Temelkova-Kurktschiev T.
Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects with Impaired Glucose Tolerance
STROKE, Vol. 35, Nu. 5, 2004: 1073-1078
Karrei K; Koehler C; Hanefeld M, Temelkova-Kurktschiev Th., del Prato St.
Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid intima-media thickening
Diabetes & Vascular Disease Research Vol. 1, May 2004: 51-52
Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross, P.
In Type 2 Diabetes, Rosiglitazone Therapy for Insulin Resistance Ameliorates Endothelial Dysfunction Independent of Glucose Control
Diabetes Care, Vol. 27, Nu. 2, February 2004: 484-490
Ceriello A, Hanefeld M, Leiter L, Monnier L, Moses A, Owens D, Tajima N, Tuomilehto J,
Postprandial Glucose Regulation and Diabetic Complications
Arch Intern Med, Vol. 164, Oct. 25, 2004; 2090-2095
Hanefeld M, Brunetti P, Schernthaner, G, Metthews D, Charbonnel B,
One-Year Glycemic Control with a Sulfonylurea plus Pioglitazone versus a Sufonylurea plus Metformin in patients with type 2 Diabetes
Diabetes Care, Vol. 27, no. 1, 2004: 141-47
Stier U, Hanefeld M.
Pathogenese des Typ-2-Diabetes
Internist. Prax. 44, 2004: 281-288
Chiasson J-L, Josse R. Gomis R, Hanefeld M, Karasik A, Laakso M and the STOP-NIDDM Trial Research Group
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM trial data
Diabetologia, May 2004
M. Hanefeld, F. Schaper, S. Rios et al
IN: The metabolic syndrome at the beginning of the XXIst century
Dyslipidemia in the Metabolic Syndrome, 347-358
M. Hanefeld, F. Schaper, C.D. Byrne, Wild S.H.
In: The Metabolic Syndrome. Treatments for the Metabolic Syndrome
Wiley Verlag, ISBN 13 978-0-470-02511-6
Temelkova-Kurktschiev T, Hanefeld M.
Epidemiology, prevalence and relevance of hypertriglyceridemia/low high-density lipoprotein syndrome in type 2 diabetes.
Exp Clin Endocrinology & Diabetes 2004 Feb;112(2):75-9
Herbrig K, Pistrosch F, Oelschlaegel U, Wichmann G, Wagner A, Foerster S, Richter S, Gross P, Passauer J:
Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis.
Am.J.Kidney Dis. 44:840-849, 2004
Gross P, Pistrosch F:
Hyperkalaemia: again.
Nephrol.Dial.Transplant. 19:2163-2166, 2004
Passauer J, Lassig G, Bussemaker E, Pistrosch F, Gross P:
Reduced endothelin-1- and nitric oxide-mediated arteriolar tone in hypertensive renal transplant recipients.
Kidney Int. 65:1782-1789, 2004
Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P:
In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.
Diabetes Care 27:484-490, 2004
2003
Hanefeld, M., Köhler, C., Fücker, K.,Henkel, E., Schaper, F., Temelkova-Kurktschiev, T.
Insulin Secretion and Insulin Sensitivity Pattern is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose
Diabetes Care, Vol. 26, Nr. 3, März 2003, S. 868-874
Hanefeld, M.; Fischer S.
Therapieentscheidung auf der Basis der Glukotrias – so stellen Sie Ihren Typ 2 Diabetiker richtig ein
MMW, 9, Febr. 2003, 30-34
Fischer S, Patzak A, Rietzsch H, Schwanebeck U, Köhler C, Wildbrett J, Fuecker K, Temelkova-Kurktschiev T, Hanefeld M
Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients
Diabetes, Obesity and Metabolism 5, 2003, 38-44
Chiasson, J.-L., Josse, R. Gomis, R. Hanefeld, M. et. Al
Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance
JAMA, July 23/2003, 486-494
In: Goldstein B. ;Müller-Wieland D.
Textbook of Type 2 Diabetes
2003, Martin Dunitz Verlag, ISBN 1 84184 109 9
Hansel S, Lassig G, Pistrosch F, Passauer J:
Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 170:177-180, 2003
Passauer J, Bussemaker E, Lassig G, Pistrosch F, Fauler J, Gross P, Fleming I:
Baseline blood flow and bradykinin-induced vasodilator responses in the human forearm are insensitive to the cytochrome P450 2C9 (CYP2C9) inhibitor sulphaphenazole.
Clin.Sci.(Lond) 105:513-518, 2003
2002
Hanefeld, M.; Temelkova-Kurktschiev, T.
Control of post-prandial hyperglycemia – an essential part of good diabetes treatment and prevention of cardiovascular complications Nutr.MetabCardiovascDis, 2002, 12: S. 98-107
Hanefeld, M., Fischer, S.
Differential therapy of type 2 diabetes based on underlying pathophysiology
Therapeutische Umschau, 8/2002, S. 393-401
Hanefeld, M.
Diabetes – eine Volkskrankheit mit steigender Tendenz und hohen Kosten
Medical economics 5/2002, S. 3
Hanefeld, M., Ott, P.
Das metabolische Risikofaktorenbündel – Typisches Syndrom unserer Zeit
Der Hausarzt 15/2002: 50-52
Hanefeld, M, Sachse, G.
The Effects of Orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes.
Journal Diabetes, Obesity and Metabolism, 2002, Nov 4 (6): 415-23
M. Kaiser, T. Temelkova-Kurktschiev and M. Hanefeld.
Intima-media thickness and atherosclerotic plaques in familial defective apolipoprotein B-100 and familial hypercholesterolemia.
Annals of New York Academy of Sciences 2002 Jun;967:528-34
Temelkova-Kurktschiev Theodora, Koehler Carsta, Henkel Elena, Hanefeld M. Leukocytes count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes.
Cardiovascular Research 2002 Nov;56(2):277-83
Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaroß W, Hanefeld M.
Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes.
Metabolism 2002 Jun;51(6):743-9
Hanefeld, M.; Haffner, S.M.; Menschikowski, M.; Koehler, C.; Temelkova-Kurktschiev, T.; Wildbrett, J. Fischer, S.
Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes
Diabetes Research and Clinical Practice 55/2002:221-227
Hanefeld, M.; Köhler, C.
Das Metabolische Syndrom im Wandel: Historische Perspektive und epidemiologische Dimension
Zeitschr. Ärztl. Fortbild.Qualit.sich. 96/2002:183-188
Hanefeld, M.; Henkel, E.
Orale Antidiabetika als Mittel zur Prävention des Typ 2 Diabetes bei Personen mit Impaired Glucose Tolerance (IGT): Ergebnisse von DPP und STOP-NIDDM
Diabetes und Stoffwechsel 11/2002: 291-296
Henkel, E., Köhler, C., Temelkova-Kurktschiev, T., Hanefeld, M.
Prädikatoren von Glukosetoleranzstörungen in einer Risikopopulation für Typ-2-Diabetes: die RIAD-Studie
DtschMedWochenschr 127, 2002, S. 953-957
Henkel, E., Temelkova-Kurktschiev, Th.,Koehler, C., Pietzsch, J., Leonhardt, W., Hanefeld M.
Impaired glucose tolerance is not associated with lipid intolerance.
Diabetes, Nutrition & Metabolism Clinical and Experimental Vol. 15, N. 2,April 2002, S. 84-90
Chiasson, JL, Josse, RG, Gomis, R, Hanefeld M, Karasik A, Laakso m, for The STOP-NIDDM Trial Research Group
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
The Lancet, Vol 359, June 15, 2002, S. 2072-2077
Temelkova-Kurktschiev Th, Hanefeld M.
Oral Glucose Tolerance Test: to be or not to be Performed?
Clinical Laboratory, Vol 48, 2002, S. 143-152
Temelkova-Kurktschiev Th., Siegert, G., Bergmann, S. Henkel, E., Koehler C., Jaroß W., Hanefeld M.
Subclinical Inflammation Is Strongly Related to Insulin Resistance But Not to Impaired Insulin Secretion in a High Risk Population for Diabetes
Metabolism, Vol 51, No 6, 2002, S. 743-749
Kopprasch, S, Pietzsch J, Kuhlisch E, Fücker K, Temelkova-Kurktschiev Th, Hanefeld M, Kühne H, Julius U, Graessler J
In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance
Diabetes, 51, 2002, 3102-3106
Metzler W, Fischer S, Köhler C. Pistrosch F, Kindel B, Hanefeld M
Insulin resistance and metabolic parameters in type 2 diabetic patients
European Jornal of Internal Medicine 13 (2002), 108-114
Chiasson J; Josse R.G;Gomis R; Hanefeld M; Karasik A; Laakso for The STOP-NIDDM Trial Research Group
Acarbose can prevent Type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance: The STOP-NIDDM trial.
Diabetologia, Vol. 45, Suppl. 2, August 2002, A 104
Temelkova-Kurktschiev T, Hanefeld M, Chineti G, Zawadzki C, Haulon S, Kubaszek A, Koehler C, Leonhardt W, Staels B, Laakso M.
Ala12Ala genotype of the peroxisome proliferator-activated receptor g2 protects against atherosclerosis.
Arteriosclerosis Thrombosis Vascular Biology 2002
Temelkova-Kurktschiev T., Koehler C., Henkel E., Hanefeld M.
Leukocytes count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes.
Cardiovascular Research 2002; 56: 277
Metzler W, Fischer S, Kohler C, Pistrosch F, Kindel B, Hanefeld M:
Insulin resistance and metabolic parameters in type 2 diabetic patients.
Eur.J.Intern.Med. 13:108-114, 2002
2001
Hanefeld M, Temelkova-Kurktschiev T.
Control of postprandial hyperglycemia – an essential part of good diabetes treatment and prevention of cardiovascular complications.
Nutrition Metabol Cardiovas 2001
Hanefeld, M.
Pharmacokonetics and clinical efficacy of pioglitazone.
International Journal of Clinical Practice 2001, Suppl. 121: 19-25
Hanefeld, M, Abletshauser, C.
Effect of the Angiotensin II Receptor Antagonist Valsartan on Lipid Profile and Glucose Metabolism in Patients with Hypertension.
The Journal of International Medical Research 2001; 29: 270-279
Hanefeld, M.
Clinical rationale for rosuvastatin, a potent new HMG-COA reductase inhibitor.
International Journal of Clinical Practice 2001, Vol 55, No 6: 399-405
Hanefeld, M
Utility of Nateglinide for Patients with Type II Diabetes.
Clinical Geriatrics. 2001
Henkel E, Temelkova-Kurktschiev Th, Koehler C, Pietzsch J, Leonhardt W, Hanefeld M.
Impaired Glucose Tolerance is not Associated with Lipid Intolerance. Diabetes Nutrition and Metabolism 2001
Klemm, T., Neumann, S., Trülzsch, B., Pistrosch, F., Hanefeld, M., Paschke, R.
Search for mitochondrial DANN mutation at position 3243 in German patients with a positive family history of meternal diabetes mellitus.
Exp Clin Endocrinol Diabetes 2001, 109: 283-287
Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M.
Subclinical inflammation in newly detected type 2 diabetes and impaired glucose tolerance.
Diabetologia 2002 Jan;45(1):151
Temelkova-Kurktschiev T, Henkel E, Köhler C, Hanefeld M.
Beziehungen der Intima-Media-Dicke (IMD) und Plaques der Karotiden und Beinarterien zu manifesten makrovaskulären Krankheiten: Die RIAD Studie.
Perfusion 2001; 14: 305-311
Temelkova-Kurktschiev T, Henkel E, Koehler C, Hanefeld M.
Light-to-moderate alcohol consumption, risk factor profile and early atherosclerosis: The RIAD Study.
Atherosclerosis 2001; 156: 239-240
Temelkova-Kurktschiev T, Fischer S, Koehler C, Mennicken G, Henkel E, Hanefeld M.
Intima-Media. Dicke bei Gesunden ohne Risikofaktoren.
DMW 2001; 126: 1-5
Hoffmann, T., Glund, K., McIntosh, Ch. Peterson, R., Hanefeld, M., Rosenkranz, B., Demuth, H.-U.
DPPIV-inhibition as treatment of type II diabetes.
Elsevier Science. 2001: 381-387
Heinle, H., Schulte, H., Hanefeld, M.:
Determinanten und Beeinflussung der Plaqueentwicklung.
14. Jahrestagung der Deutschen Gesellschaft für Arterioskleroseforschung 2000. Tübingen: Deutsche Gesellschaft für Arterioskleroseforschung, 2001. S. 62-66
Klemm T, Neumann S, Trulzsch B, Pistrosch F, Hanefeld M, Paschke R:
Search for mitochondrial DNA mutation at position 3243 in German patients with a positive family history of maternal diabetes mellitus.
Exp.Clin.Endocrinol.Diabetes 109:283-287, 2001